Outcomes of Primary Percutaneous Coronary Intervention in Patients With a Thrombolysis in Myocardial Infarction Score of Five or Higher.
acute stemi
adverse events
primary percutaneous coronary intervention
timi score ≥ 5
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
23 Jul 2020
23 Jul 2020
Historique:
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Background Primary percutaneous coronary intervention (PCI) is a treatment of choice for patients with ST-segment elevation myocardial infarction (STEMI). Of the various risk stratification scores that have been introduced, the thrombolysis in myocardial infarction (TIMI) score is among the most used modalities. Patients with a TIMI score of five or higher are classified as high-risk patients with higher rates of adverse events. Therefore, this study aimed to determine the rate of adverse events after primary PCI in patients presenting with STEMI and a TIMI score of five or higher. Methodology This descriptive study was conducted at the cardiology department of the Liaquat National Hospital, Karachi, from February 2018 to August 2018. The patients included in this study consisted of a total of 150 men and women who presented to the ED with concerns of chest pain and were diagnosed with STEMI and had a TIMI score of five or higher. Consultant cardiologists performed primary PCI procedures, and any post-procedure adverse events were recorded during the patients' hospital stays (up to one week), including mortality, heart failure, cardiogenic shock, and ventricular arrhythmias. Results The study population was 83.3% male and 16.7% female patients, and the mean age was 54.0 ± 9.4 years. The mean BMI was 27.34 ± 2.76 kg/m
Identifiants
pubmed: 32850228
doi: 10.7759/cureus.9356
pmc: PMC7444986
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e9356Informations de copyright
Copyright © 2020, Talreja et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2019 Jul 25;14(7):e0220289
pubmed: 31344139
Circulation. 2000 Oct 24;102(17):2031-7
pubmed: 11044416
EuroIntervention. 2014 Jan 22;9(9):1095-101
pubmed: 24457280
Minerva Cardioangiol. 2018 Oct;66(5):576-593
pubmed: 29642691
CMAJ. 2010 Jul 13;182(10):1039-44
pubmed: 20530163
Int J Cardiol. 2019 Nov 1;294:27-31
pubmed: 31387823
Arq Bras Cardiol. 2014 Aug;103(2):98-106
pubmed: 25029471
Can J Cardiol. 2015 Sep;31(9):1151-9
pubmed: 26321437
Indian Heart J. 2020 May - Jun;72(3):166-171
pubmed: 32768015
Int J Cardiol. 2017 Jan 15;227:656-661
pubmed: 27810290
J Am Heart Assoc. 2016 May 20;5(5):
pubmed: 27207959
PLoS One. 2015 Apr 20;10(4):e0123215
pubmed: 25893501
Arq Bras Cardiol. 2010 May;94(5):613-9
pubmed: 20428718
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
BMJ. 2017 Apr 11;357:j1420
pubmed: 28400361
Circulation. 2018 Jul 3;138(1):e1-e34
pubmed: 29794080
Arch Cardiol Mex. 2012 Jan-Mar;82(1):7-13
pubmed: 22452860
Circ Res. 2017 Sep 1;121(6):677-694
pubmed: 28860318
Glob Heart. 2019 Sep;14(3):335-341
pubmed: 31451242
Am Heart J. 2005 Sep;150(3):402-10
pubmed: 16169316